<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00877877</url>
  </required_header>
  <id_info>
    <org_study_id>111375</org_study_id>
    <nct_id>NCT00877877</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.</brief_title>
  <official_title>Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of a HPV Vaccine (GSK 580299) in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the necessary cause
      of cervical cancer. This study is designed to evaluate the long-term immunogenicity and
      safety of the 580299 HPV vaccine up to 10 years after administration of the first dose of HPV
      vaccine (Month 0) administered in the primary study 580299/013. This protocol posting deals
      with objectives &amp; outcome measures of the extension phase from Month 60 to Month 120. The
      objectives &amp; outcome measures of the primary phase are presented in a separate protocol
      posting (NCT00196924). The objectives &amp; outcome measures of the extension phase up to Month
      48 are presented in a separate protocol posting (NCT00316706).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were aged 10-14 years at the time of entry into the primary study. No vaccine will
      be administered in this extension study.

      Results on outcome measures describing analyses on other studies are not reported in this
      record. Please refer to the records mentioned in the respective outcome measure titles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</measure>
    <time_frame>At Month 60</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</measure>
    <time_frame>At Month 72</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</measure>
    <time_frame>At Month 84</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</measure>
    <time_frame>At Month 96</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</measure>
    <time_frame>At Month 60</time_frame>
    <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</measure>
    <time_frame>At month 72</time_frame>
    <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</measure>
    <time_frame>At Month 84</time_frame>
    <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</measure>
    <time_frame>At Month 96</time_frame>
    <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</measure>
    <time_frame>At Month 108</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</measure>
    <time_frame>At Month 108</time_frame>
    <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</measure>
    <time_frame>At Month 120</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</measure>
    <time_frame>At Month 120</time_frame>
    <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 48 to Month 60</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 60 to Month 72</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 72 to Month 84</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 84 to Month 96</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 96 to Month 108</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 108 to Month 120</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">632</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120</description>
    <arm_group_label>Cervarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parents or legally
             acceptable representative (LAR) can and will comply with the requirements of the
             protocol should be enrolled in the study.

          -  A female enrolled in the immunogenicity subset of study 580299-013, who received three
             doses of HPV vaccine and participated in the extension study of 580299-013.

          -  Written informed assent obtained from the subject. For subjects below the legal age of
             consent, written informed consent must be obtained from a parent or legally acceptable
             representative of the subject.

        Exclusion Criteria:

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Use of any investigational or non-registered product (drug or vaccine) or planned use
             during the study period.

          -  Administration or planned administration of any HPV vaccine, other than the vaccine
             administered in study 580299-013.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs occurring
             within the three months preceding study entry.

          -  Administration of immunoglobulins and/or any blood products occurring within the three
             months preceding study entry.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauberbischofsheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>97941</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weilheim</city>
        <state>Bayern</state>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buetzow</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolfenbuettel</city>
        <state>Niedersachsen</state>
        <zip>38302</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44866</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willich</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47877</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrislee</city>
        <state>Schleswig-Holstein</state>
        <zip>24955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niebuell</city>
        <state>Schleswig-Holstein</state>
        <zip>25899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weimar</city>
        <state>Thueringen</state>
        <zip>99423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tegucigalpa</city>
        <state>Francisco Morazan</state>
        <zip>11101</zip>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arraijan/Vista Alegre</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Chorrera</city>
        <state>Panamá</state>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Honduras</country>
    <country>Panama</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <results_first_submitted>March 31, 2011</results_first_submitted>
  <results_first_submitted_qc>March 31, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2011</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccine</keyword>
  <keyword>cervical cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111375</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects who participated in the primary study (NCT00196924) and received 3 doses of Cervarix.</recruitment_details>
      <pre_assignment_details>Subjects enrolled in this study were primed with Cervarix vaccine as part of study NCT00196924. Subjects not returning for a specific visit were not withdrawn and could participate in the subsequent follow-up phases. Actual enrollment differed depending on the rate of return for the follow-up study, so not all subjects enrolled came to each visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 7</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="523"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="523"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 8</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 9</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 10</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="495"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="495"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="529"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.0" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 5 cohort</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 6 cohort</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 7 cohort</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 8 cohort</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 9 cohort</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Year 10 cohort</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 60</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 60 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 60 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 60 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 60 blood sampling timepoint.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 Month 60 [N=353]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 Month 60 [N=358]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 72</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 72 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 72 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 72 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 72 blood sampling timepoint.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 Month 72 [N=475]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 Month 72 [N=478]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 84</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 84 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 84 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 84 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 84 blood sampling timepoint.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 Month 84 [N=469]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 Month 84 [N=473]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 96</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 96 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 96 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL.
Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination.
A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 96 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 96 blood sampling timepoint.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 Month 96 [N=473]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 Month 96 [N=477]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
        <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 60</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 60 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 60 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
          <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 60 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 60 blood sampling timepoint.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 Month 60 [N=376]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2262.9" lower_limit="2069.1" upper_limit="2475.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 Month 60 [N=376]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="778.6" lower_limit="703.1" upper_limit="862.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
        <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
        <time_frame>At month 72</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 72 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 72 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
          <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 72 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 72 blood sampling timepoint.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 Month 72 [N=502]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1973.9" lower_limit="1827.9" upper_limit="2131.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 Month 72 [N=502]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="762.8" lower_limit="701.0" upper_limit="830.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
        <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 84</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 84 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 84 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
          <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 84 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 84 blood sampling timepoint.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-016 Month 84 [N=494]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1756.7" lower_limit="1622.7" upper_limit="1901.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-018 Month 84 [N=494]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609.7" lower_limit="559.0" upper_limit="664.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
        <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 96</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 96 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 96 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
          <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 96 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 96 blood sampling timepoint.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>anti-HPV-16 Month 96 [N=499]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1671.0" lower_limit="1548.1" upper_limit="1803.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anti-HPV-18 Month 96 [N=499]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679.0" lower_limit="623.5" upper_limit="739.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 108</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 108 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 108 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 108 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 108 blood sampling timepoint.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 Month 108 [N=374]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 Month 108 [N=370]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
        <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
        <time_frame>At Month 108</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 108 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 108 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
          <description>Anti-HPV-16 and 18 antibody titers are given in Geometric Mean Titers (GMTs) in Enzyme-linked Immunosorbent Assay (ELISA) Units per milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 108 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 108 blood sampling timepoint.</population>
          <units>EL.U/ML</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 Month 108 [N=392]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1946.5" lower_limit="1779.7" upper_limit="2128.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 Month 108 [N=391]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="754.0" lower_limit="685.4" upper_limit="829.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 120</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 120 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 120 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-human Papillomavirus-16 and 18 (Anti-HPV-16/18) Antibody Titers</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 120 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 120 blood sampling timepoint.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 Month 120 [N=416]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1607.9" lower_limit="1480.8" upper_limit="1746.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 Month 120 [N=415]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608" lower_limit="552.5" upper_limit="669.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
        <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
        <time_frame>At Month 120</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 120 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 120 blood sampling timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values.</title>
          <description>Anti-HPV-16 assay cut-off value was defined as 8 ELISA units per milliliter (EL.U/mL). Anti-HPV-18 assay cut-off value was defined as 7 EL.U/mL. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. A seronegative subject is a subject with antibody titer &lt; 8 or 7 EL.U/mL prior to vaccination. A seropositive subject is a subject with antibody titer &gt;= 8 or 7 EL.U/mL prior to vaccination.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity Month 120 which included all evaluable subjects from the primary study (NCT00196924) for whom serology results were available at the Month 120 blood sampling timepoint.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV-16 Month 120 [N=393]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV-18 Month 120 [N=395]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 48 to Month 60</time_frame>
        <population>The analysis was performed on the Month 60 Total Vaccinated cohort, which included all vaccinated subjects (who had received 3 doses during the primary study (NCT00196924)) for whom data were available for the Month 60 time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Month 60 Total Vaccinated cohort, which included all vaccinated subjects (who had received 3 doses during the primary study (NCT00196924)) for whom data were available for the Month 60 time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 60 to Month 72</time_frame>
        <population>Analysis was performed on the Month 72 Total Vaccinated cohort, which included all vaccinated subjects (who had received 3 doses during the primary study (NCT00196924)) for whom data were available for the Month 72 time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Month 72 Total Vaccinated cohort, which included all vaccinated subjects (who had received 3 doses during the primary study (NCT00196924)) for whom data were available for the Month 72 time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 72 to Month 84</time_frame>
        <population>Analysis was performed on the Month 84 Total Vaccinated cohort, which included all vaccinated subjects (who had received 3 doses during the primary study (NCT00196924)) for whom data were available for the Month 84 time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Month 84 Total Vaccinated cohort, which included all vaccinated subjects (who had received 3 doses during the primary study (NCT00196924)) for whom data were available for the Month 84 time point.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 84 to Month 96</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 96 to Month 108</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 108 to Month 120</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events were assessed by time intervals: Months 48-60, Months 60-72, Months 72-84, Months 84-96, Months 96-108 and Months 108-120.</time_frame>
      <desc>Other (non-serious) Adverse Events were not collected/assessed during this long-term follow-up study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group From Month 48 Until Month 60</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule and for whom serious adverse events were collected from Month 48 until Month 60.</description>
        </group>
        <group group_id="E2">
          <title>Cervarix Group From Month 60 Until Month 72</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule and for whom serious adverse events were collected from Month 60 until Month 72.</description>
        </group>
        <group group_id="E3">
          <title>Cervarix Group From Month 72 to Month 84</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule and for whom serious adverse events were collected from Month 72 until Month 84.</description>
        </group>
        <group group_id="E4">
          <title>Cervarix Group From Month 84 to Month 96</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule and for whom serious adverse events were collected from Month 84 until Month 96.</description>
        </group>
        <group group_id="E5">
          <title>Cervarix Group From Month 96 to Month 108</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule and for whom serious adverse events were collected from Month 96 until Month 108.</description>
        </group>
        <group group_id="E6">
          <title>Cervarix Group From Month 108 to Month 120</title>
          <description>Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule and for whom serious adverse events were collected from Month 108 until Month 120.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Skull malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Congenital megaureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pulmonary malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Crohn’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hodgkin’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Olygohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Cervical incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Neonatal tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="397"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="529"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="522"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

